Phosphagenics reports pain relief
Monday, 08 December, 2008
Phosphagenics has completed a Phase I trial for its drug delivery system TPM to deliver lidocaine topically.
The trial, to assess the bioavailability, safety and tolerability of the application, found the formulation was able to deliver more of the pain relief drug to the skin compared to a leading commercial product, Xylocaine, marketed by AstraZeneca.
The open label, single centre study was conducted at the Centre for Pharmaceutical Research at the University of South Australia in 11 healthy adult volunteers.
TPM is being trialled in a number of small molecule delivery applications, including hormones, morphine and oxycodone. It is also being expanded to large molecule applications, such as peptides.
The company’s lead product is Phospha E, a vitamin E derivative it is exploring as a neutraceutical.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
